Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market ...

Under the agreement, Biocon will supply semaglutide to Ajanta Pharma for exclusive marketing in 23 countries Shares of Ajanta ...

Hindustan Copper hits new high, Tata Capital settles SEBI case, Ola Electric and Ajanta Pharma in focus amid a flat market ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...

Mumbai-based Ajanta Pharma has entered into an agreement with Biocon to commercialise its version of semaglutide across ...

Semalutide improves glycaemic control in adults. The product patent expires in most these markets in March 2026. Ajanta ...

Biocon will supply Semaglutide to Ajanta Pharma for exclusive marketing in 23 countries and semi-exclusive marketing in three countries across Africa, West Asia, and Central Asia ...

Ajanta Pharma, JBMA Auto and Manappuram Finance have seen strong price action backed by heavy trading volume in Wednesday's ...

Ajanta Pharma inked an in-licensing agreement with Biocon Ltd. for semaglutide, a GLP-1 receptor agonist. Zydus Lifesciences ...

Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent ...

Biotech firm Biocon on Tuesday said it has signed an out-licensing agreement with Ajanta Pharma to market its diabetes drug ...

Emcure Pharmaceuticals has informed the exchanges that the United States Food and Drug Administration (USFDA) has issued a No ...